A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease

被引：62

作者：

Bodini, Giorgia ^{[1
]}

Zanella, Claudia ^{[1
]}

Crespi, Mattia ^{[1
]}

Lo Pumo, Sara ^{[1
]}

Demarzo, Maria Giulia ^{[1
]}

Savarino, Edoardo ^{[1
]}

Savarino, Vincenzo ^{[1
]}

Giannini, Edoardo G. ^{[1
]}

机构：

[1] Univ Genoa, Dept Internal Med, Gastroenterol Unit, Osped Policlin San Martino IRCCS Oncol, Genoa, Italy

来源：

NUTRITION | 2019年 / 67-68卷

关键词：

Diet; Irritable bowel syndrome; Inflammatory bowel disease; Disease activity; Calprotectin; C-reactive protein; FUNCTIONAL GASTROINTESTINAL DISORDERS; QUALITY-OF-LIFE; CROHNS-DISEASE; SYMPTOMS; PREVALENCE; RESTRICTION; EFFICACY; IMPACT;

D O I：

10.1016/j.nut.2019.06.023

中图分类号：

R15 [营养卫生、食品卫生]; TS201 [基础科学];

学科分类号：

100403 ;

摘要：

Objective: The aim of this study was to assess the safety and efficacy of a low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet (LFD) in patients with inflammatory bowel disease (IBD). Methods: An LFD is associated with symptom improvement in patients with functional intestinal disorders, although its safety and efficacy has not been characterized in patients with IBD. Fifty-five patients with IBD in remission or with mild disease activity were randomized to a 6-wk LFD or standard diet (SD). Disease activity (Harvey Bradshaw index [HBi], partial Mayo score), fecal calprotectin, and disease-specific quality of life (IBD-Q) were assessed at baseline and at the end of dietary intervention. Results: After the 6-wk dietary intervention, median HBi decreased in the LFD (4; IQR, 3-5 versus 3; IQR, 2-3; P = 0.024) but not in the SD (3; IQR, 3-3 versus 3; IQR, 2-4), whereas Mayo scores were numerically decreased in the LFD group and unmodified in the SD group. Median calprotectin decreased in the LFD (76.6 mg/kg; IQR, 50-286.3 versus 50 mg/kg; IQR, 50.6-81; P = 0.004) but not in the SD group (91 mg/kg; IQR, 50.6-143.6 versus 87 mg/kg; IQR, 50-235.6). Lastly, we observed a barely significant increase in median IBD-Q in the LFD group (166; IQR, 139-182 versus 177; IQR, 155-188; P=0.05) and no modification in the SD group (181; IQR, 153-197 versus 166; IQR, 153-200). Conclusions: A short-term, LFD is safe for patients with IBD, and is associated with an amelioration of fecal inflammatory markers and quality of life even in patients with mainly quiescent disease. (C) 2019 Elsevier Inc. All rights reserved.

引用

页数：7

共 35 条

[1]

Ahluwalia B, 2018, SCAND J GASTROENTERO, V9, P1

[2] Diet, Gut Microbiome and Epigenetics: Emerging Links with Inflammatory Bowel Diseases and Prospects for Management and Prevention [J].

Aleksandrova, Krasimira ;

Romero-Mosquera, Beatriz ;

Hernandez, Vicent .

NUTRIENTS, 2017, 9 (09) :1-13

[3] Dietary intake of inulin-type fructans in active and inactive Crohn's disease and healthy controls: a case-control study [J].

Anderson, Jacqueline L. ;

Hedin, Charlotte R. ;

Benjamin, Jane L. ;

Koutsoumpas, Andreas ;

Ng, Siew C. ;

Hart, Ailsa L. ;

Forbes, Alastair ;

Stagg, Andrew J. ;

Lindsay, James O. ;

Whelan, Kevin .

JOURNAL OF CROHNS & COLITIS, 2015, 9 (11) :1024-1031

[4] Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status [J].

Barratt, HS ;

Kalantzis, C ;

Polymeros, D ;

Forbes, A .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (02) :141-147

[5] Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lemann Index [J].

Bodini, Giorgia ;

Giannini, Edoardo G. ;

De Maria, Costanza ;

Dulbecco, Pietro ;

Furnari, Manuele ;

Marabotto, Elisa ;

Savarino, Vincenzo ;

Savarino, Edoardo .

DIGESTIVE AND LIVER DISEASE, 2017, 49 (02) :175-180

[6] Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease [J].

Bodini, Giorgia ;

Giannini, Edoardo G. ;

Savarino, Vincenzo ;

Del Nero, Lorenzo ;

Pellegatta, Gaia ;

De Maria, Costanza ;

Baldissarro, Isabella ;

Savarino, Edoardo .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (09) :1081-1086

[7] Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial [J].

Cox, Selina R. ;

Prince, Alexis C. ;

Myers, Clio E. ;

Irving, Peter M. ;

Lindsay, James O. ;

Lomer, Miranda C. ;

Whelan, Kevin .

JOURNAL OF CROHNS & COLITIS, 2017, 11 (12) :1420-1429

[8] Pilot study on the effect of reducing dietary FODMAP intake on bowel function in patients without a colon [J].

Croagh, Catherine ;

Shepherd, Susan J. ;

Berryman, Melissa ;

Muir, Jane G. ;

Gibson, Peter R. .

INFLAMMATORY BOWEL DISEASES, 2007, 13 (12) :1522-1528

[9] Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV [J].

Drossman, Douglas A. .

GASTROENTEROLOGY, 2016, 150 (06) :1262-+

[10] Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: Prevalence and impact on health [J].

Farrokhyar, F ;

Marshall, JK ;

Easterbrook, B ;

Irvine, EJ .

INFLAMMATORY BOWEL DISEASES, 2006, 12 (01) :38-46

← 1 2 3 4 →